Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) announced that patient enrollment in its collaborative multiple sclerosis imaging study with Massachusetts General Hospital has reached the halfway mark, with preliminary imaging data showing encouraging signal in acute MS lesions and potential sensitivity to gray matter lesions. The study is evaluating a novel PET imaging technique using the [¹⁸F]3F4AP tracer to directly assess demyelination, which the company believes could enhance development of MS therapies including its investigational candidate Lucid-MS, for which an IND submission for a Phase 2 trial was submitted to the FDA in March 2026.
This milestone is significant because it validates the feasibility of the imaging approach and provides early evidence that the tracer can detect active demyelination in patients. The ability to visualize gray matter lesions, which are often missed by conventional MRI, could transform how MS progression is monitored and how therapies are evaluated. For Quantum BioPharma, positive results from this study may support the clinical development of Lucid-MS, a patented new chemical entity that has shown ability to prevent and reverse myelin degradation in preclinical models.
The company submitted an IND for a Phase 2 trial of Lucid-MS to the FDA in March 2026, and the imaging data could provide biomarkers to assess treatment response. The study with Massachusetts General Hospital is a key part of Quantum's strategy to advance its pipeline in neurodegenerative diseases. The company also retains a 19.84% stake in Unbuzzd Wellness Inc., which markets the OTC hangover remedy UNBUZZD, and receives royalty payments of 7% of sales until $250 million is reached, after which the royalty drops to 3% in perpetuity.
Investors can view the full press release at https://ibn.fm/4IZ0y and stay updated on Quantum BioPharma news at https://ibn.fm/QNTM. Forward-looking statements in this article involve risks and uncertainties detailed in the company's SEC filings.
